Compare Summit Therapeutics Inc (SMMT) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Summit Therapeutics Inc trades at $17.4 (market cap $13.71B), while Vanguard Dividend Appreciation Index Fund ETF trades at $238.94 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 9.7× Summit Therapeutics Inc's market cap, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Vanguard Dividend Appreciation Index Fund ETF for 133 Days on average.
| SMMT | VIG | |
|---|---|---|
Market Cap | $13.71B | $132.40B |
Volume | 6,173,057 | 1,287,188 |
Sector | Health | — |
52-Week High | $26.38 | $246.61 |
52-Week Low | $12.43 | $210.70 |
Typical Hold Time | 16 Days | 133 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
VIG trades at $237.99, up 0.42% with a bullish technical signal from moving averages. The ETF focuses on dividend growth companies with 10+ years of consecutive dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent news highlights its 7.5% quarterly dividend increase and long-term return potential averaging 10% annually since inception.
Outlook remains positive for investors seeking dividend growth with moderate risk, though the low current yield and exclusion of high-yield stocks present trade-offs. Key risks include market volatility and the ETF's specific eligibility rules limiting certain holdings. The growth-oriented strategy appeals to long-term investors prioritizing increasing income over current yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
